Accession Therapeutics Limited
Andy Johnson is an experienced pharmaceutical professional currently serving as the Head of CMC at Accession Therapeutics Limited since February 2022, where responsibilities include overseeing the development of Active Pharmaceutical Ingredients and Investigational Medicinal Products from pre-clinical stages to clinical readiness. Prior to this role, Andy held multiple positions at Immunocore from September 2008 to February 2022, culminating as Director of Manufacturing and Outsourcing, with a focus on external manufacturing for clinical and commercial programs. Previous experience includes Development Group Leader roles at MediGene AG and Avidex, along with Development Scientist positions at Lonza and British Biotech, showcasing a strong background in pharmaceutical development and scientific leadership.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.